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Clinical PerspectiveWhat Is New?Limited comparative research on new‐generation heat‐not‐burn cigarettes, electronic vaping cigarettes, and traditional tobacco combustion cigarettes (TCs) has been reported.We performed a cross‐over, randomized trial in 20 TC smokers, with allocation to different cycles of heat‐not‐burn cigarettes, electronic vaping cigarettes, and TCs, without any funding from tobacco or electronic vaping cigarette companies.What Are the Clinical Implications?We found that acute effects of heat‐not‐burn cigarettes, electronic vaping cigarettes, and TCs are different on several oxidative stress, antioxidant reserve, platelet function, cardiovascular, and satisfaction dimensions, with TCs showing the most detrimental changes in clinically relevant features, thus suggesting that these modified risk products may indeed prove as a useful tool to quit TCs.

Introduction {#jah33811-sec-0009}
============

It is estimated that cigarette smoking explains almost 90% of lung cancer risk in men and 70% to 80% in women and is responsible for ≈140 000 premature deaths annually from cardiovascular disease.[1](#jah33811-bib-0001){ref-type="ref"}, [2](#jah33811-bib-0002){ref-type="ref"} Among the different harmful effects of smoking, oxidative stress plays an important role. Indeed, smoking may impair oxidative balance by inducing the production of reactive oxygen species and by weakening the antioxidant defense systems. Moreover, smoking promotes atherothrombosis by inducing platelet activation, and we previously demonstrated that chronic smokers displayed different levels of biomarkers of oxidative stress and platelet activation compared with nonsmokers, and also responded differently to different types of cigarettes.[3](#jah33811-bib-0003){ref-type="ref"}, [4](#jah33811-bib-0004){ref-type="ref"}

Electronic vaping cigarettes (EVCs), modern technological surrogates of traditional tobacco combustion cigarettes (TCs), were introduced in 2004.[5](#jah33811-bib-0005){ref-type="ref"}, [6](#jah33811-bib-0006){ref-type="ref"} They are battery‐operated aerosolizing devices using liquids that entail a mixture of glycerol and propylene glycol, flavors, and, most commonly, nicotine ranging from 1.6 to 19 mg/cartridge.[7](#jah33811-bib-0007){ref-type="ref"} EVCs are considered a relatively less harmful alternative to TCs given that no combustion occurs, and indeed several patent applications describe EVCs as electronic atomization cigarettes that contain only nicotine without tobacco tar.[8](#jah33811-bib-0008){ref-type="ref"} However, their long‐term safety remains largely uncertain, especially in patients with established clinical disease.[9](#jah33811-bib-0009){ref-type="ref"}

A new‐generation heat‐not‐burn cigarette (HNBC) has been recently introduced.[10](#jah33811-bib-0010){ref-type="ref"} This device heats a disposable tobacco stick with a thin metallic blade. The stick is maintained at a controlled heating temperature up to 350°C, without combustion, fire, ash, or smoke. In addition, in contrast to EVCs, HNBCs do not vaporize liquid‐containing flavorings, propylene glycol, and vegetable glycerol. However, this new device needs to be fully examined in clinical studies, particularly in the cardiovascular system.[11](#jah33811-bib-0011){ref-type="ref"}

Recently, we and others highlighted the acute adverse effects in vivo and in vitro of EVCs on vascular function, oxidative stress, and platelet activation, which are recognized as pathophysiological factors for atherosclerosis development and progression and, ultimately, vascular disease.[12](#jah33811-bib-0012){ref-type="ref"}, [13](#jah33811-bib-0013){ref-type="ref"}, [14](#jah33811-bib-0014){ref-type="ref"} Specifically, we found that EVCs had less impact than TCs on oxidative stress, flow‐mediated dilation (FMD), and platelet aggregation. Moreover, Nabavizadeh et al demonstrated that, in rats, acute exposures to HNBC aerosol impairs endothelial function, assessed by FMD.[15](#jah33811-bib-0015){ref-type="ref"} However, no independent comparative data on the acute impact of HNBCs on vascular function, oxidative stress, and platelet activation are available in chronic TC users.

We thus aimed at comparing HNBCs, EVCs, and TCs, focusing on acute effects on oxidative stress, FMD, platelet function, blood pressure, and satisfaction.

Methods {#jah33811-sec-0010}
=======

The data, analytical methods, and study materials of this trial will be made available to other researchers for purposes of reproducing the results or replicating the procedure, upon written request.

Design {#jah33811-sec-0011}
------

This was an independent, randomized, cross‐over study conducted in 2017 at Sapienza University of Rome, Latina, Italy. All participants provided written informed consent. The study was approved by the ethics committee of Sapienza University of Rome (06‐27‐2014, protocol number 813/14) and conducted in accord with the Declaration of Helsinki. No funding, directly or indirectly, was received from any HNBC, EVC, or TC manufacturer or supplier, or affiliated organizations.

Participants {#jah33811-sec-0012}
------------

We recruited apparently healthy subjects, on the basis of the following: (1) no acute or chronic organic, metabolic, and inflammatory disease; (2) no fever or infection within 3 months; (3) no cardiovascular symptoms; (4) no allergies; and (5) normal blood pressure levels and heart rhythm at screening. Women were not pregnant and not menstruating when the experiment was performed. In the month preceding the study and subsequently, none of the participants took vitamin E, other antioxidant supplements, or other drugs known to affect or modulate oxidative stress, FMD, platelet function, or blood pressure. A 1‐week washout from any tobacco product was recommended at study entry and before each experimental cycle, and smoking history (time when smoking had begun) and intensity (ie, number of daily cigarettes) was self‐reported.

Procedures {#jah33811-sec-0013}
----------

Participants were previously tutored on how to use the different devices correctly by means of standardized videos. They were then randomly allocated to 6 different cycles of using a single HNBC, EVC, and TC. Participants either smoked a single TC from a leading brand (Marlboro Gold; Philip Morris International, Neuchatel, Switzerland) with a mean nicotine content of 0.60 mg per cigarette according to the package label, vaped 9 puffs from a leading tobacco‐flavored EVC (Blu Pro, Fontem, Netherlands), charged with a nicotine cartridge with a mean nicotine content of 16 mg, equivalent to 250 puffs according to the package label, thus yielding 0.58 mg of nicotine content in 9 puffs, or used a leading HNBC (THS2.2 IQOS with Heets; Amber Label, Philip Morris International) having a mean nicotine content of 0.50 mg per stick according to the manufacturer. Two investigators (who were past smokers or current users of all the devices) directly supervised all sessions to prevent incorrect product use or hyperventilation.

The randomization list was computer generated, and subjects were unaware of the assignment until each smoking session commenced. Participants eventually used all 3 products, with an intercycle washout period of 1 week. Blood samples were drawn just before and immediately after using each allocated product and analyzed for markers of oxidative stress, antioxidant reserve, platelet function, and cotinine levels. Endothelial dysfunction (as assessed by FMD) and cardiovascular parameters were analyzed, as previously reported.[12](#jah33811-bib-0012){ref-type="ref"}

A 7‐question product satisfaction questionnaire was administrated after each smoking session, posing the following questions: "was the cigarette satisfying?"; "was the cigarette enjoyable?"; "did you experience a bad taste?"; "did you suffer from unexpected cough?"; "did smoking make you feel sick?"; "did smoking give you energy?"; and "soon after smoking did your desire for another cigarette decrease?". Each feature was scored using a visual analogue scale, spanning from 0 (no effect) to 100 (maximum effect) according to Shiffman and Terhorst.[16](#jah33811-bib-0016){ref-type="ref"}

All measurements were conducted by personnel blinded to the actual product used by the participant during each experimental session.

Laboratory Analysis {#jah33811-sec-0014}
-------------------

All materials for laboratory tests were from Sigma‐Aldrich (St. Louis, MO), unless otherwise specified. Blood obtained from subjects was collected in blood collection tubes with or without anticoagulant and centrifuged at 300*g* for 10 minutes to obtain supernatant. Serum and plasma samples were instantly stored at −80°C until use with the antioxidant butylated hydroxytoluene at a final concentration of 20 mmol/L.

Ultrasound assessment of basal brachial diameter and endothelial‐dependent FMD of the brachial artery were investigated according to current guidelines.[16](#jah33811-bib-0016){ref-type="ref"}, [17](#jah33811-bib-0017){ref-type="ref"} Briefly, the study was performed in a temperature‐controlled room (22.8°C) with subjects in a resting, supine state. All evaluations were performed between 8 and 10 [am;]{.smallcaps} brachial artery diameter was imaged using a 7.5‐MHz linear array transducer ultrasound system (Vivid S6; GE Healthcare, Little Chalfont, UK) equipped with electronic callipers, vascular software for 2‐dimensional imaging, color and spectral Doppler, and internal ECG. The brachial artery was imaged at a location 3 to 7 cm above the antecubital crease. In order to create a flow stimulus in the brachial artery, a sphygmomanometric cuff was placed on the forearm. The cuff was inflated at least 50 mm Hg above systolic pressure to occlude artery inflow for 5 minutes. All vasodilatation measurements were made at the end of diastole. FMD was expressed as change in poststimulus diameter evaluated as percentage of the baseline diameter.[18](#jah33811-bib-0018){ref-type="ref"}

Serum levels of soluble Nox2‐derived peptide, a marker of NADPH oxidase activation, were detected by an ELISA method as previously described by Carnevale et al.[19](#jah33811-bib-0019){ref-type="ref"} Intra‐ and interassay coefficients of variation were 8.9% and 9%, respectively. Values are expressed as pg/mL.

Nitric oxide bioavailability was measured in serum by a colorimetric assay kit (Arbor Assays, Ann Arbor, MI). Intra‐ and interassay coefficients of variation were 4.4% and 6.8%, respectively. Values are expressed as μmol/L.

Quantification of isoprostanes was performed measuring serum 8‐iso‐PGF2α‐III (8‐iso‐PGF2α‐III) by enzyme immunoassay method (DRG International, Springfield, NJ). Intra‐ and interassay coefficients of variation were 5.8% and 5.0%, respectively. Values are expressed as pmol/L.

H~2~O~2~ was evaluated by a colorimetric detection kit (Arbor Assays) and is expressed as μmol/L. Intra‐ and interassay coefficients of variation were 5.9% and 7.3%, respectively.

Serum H~2~O~2~ breakdown activity (HBA) was measured with an HBA assay kit (Aurogene, Rome, Italy). Briefly, serum sample (2.5 μL) was incubated with H~2~O~2~ and sample diluent at 37°C for 30 minutes. At the end of 30 minutes, stop solution was added and samples were then centrifuged at 3000 g for 5 minutes. Finally, the supernatant was read at 230 nm by a UV‐visible single‐beam spectrophotometer (A380; AOE Instruments Shangai Co, Shangai, China). Percentage of HBA was calculated according to the following formula: % Of HBA=\[(Ac−As)/Ac\]×100 where Ac is the absorbance of H~2~O~2~ 1.4 mg/mL and As is the absorbance in the presence of the serum sample.

To measure vitamin E, serum samples (100 μL) were supplemented with tocopheryl acetate (internal standard), deproteinized by the addition of methanol, and centrifuged at 3000*g* for 10 minutes, as previously described.[20](#jah33811-bib-0020){ref-type="ref"} The collected upper phase was analyzed using an Agilent 1200 Infinity series high‐performance liquid chromatography system (Agilent Technologies, Santa Clara, CA) equipped with an Eclipse Plus C18 column (4.6×100 mm). Vitamin E levels are presented as the ratio (μmol/mmol) between α‐tocopherol concentration (μmol/L) and serum total cholesterol concentration (mmol/L).[21](#jah33811-bib-0021){ref-type="ref"}

Platelet levels of soluble CD40L and P‐selectin were measured in citrated blood samples centrifuged 15 minutes at 3000*g*. sCD40L levels were evaluated by a commercial immunoassay (Diaclone, Besancon, France), and values are expressed as ng/mL; intra‐ and interassay coefficients of variation were 4% and 6.8%, respectively. Soluble P‐selectin levels were evaluated by a commercial immunoassay (Diaclone), and values are expressed as ng/mL; intra‐ and interassay coefficients of variation were 5.6% and 7.5%, respectively.

Serum levels of cotinine, a metabolite of nicotine and the primary biomarker for the determination of tobacco exposure,[22](#jah33811-bib-0022){ref-type="ref"} were evaluated by a commercial immunoassay (Origene, Rockville, MD), and values are expressed as ng/mL; intra‐ and interassay coefficients of variation were \<10%.

Finally, we also measured systolic, diastolic, and mean blood pressure with an automated sphygmomanometer, averaging 3 measurements taken 3 minutes apart.

Notably, blood draws and blood pressure measurements were performed on the dominant arm (with blood draws preceding blood pressure measurements), whereas FMD was measured on the nondominant arm of each participant (Figure [S1](#jah33811-sup-0001){ref-type="supplementary-material"}).

End Points and Analyses {#jah33811-sec-0015}
-----------------------

End points were blood levels of soluble Nox2‐derived peptide, nitric oxide (NO) bioavailability, H~2~O~2~, HBA, 8‐iso‐PGF2α‐III, vitamin E, CD40 ligand, P‐selectin, cotinine FMD, blood pressure, and subjective satisfaction scores.

Statistical Analysis {#jah33811-sec-0016}
--------------------

Continuous variables are reported as means (SD) and categorical variables as counts (percentage). The main inferential analysis was based on a multilevel mixed‐effects linear model, with an identity covariance matrix, forcing in the model each end point value, timing of sampling, product type, and their interaction as fixed effects, with participant and order as random effects (Data [S1](#jah33811-sup-0001){ref-type="supplementary-material"}), similar to the model already used for the SUR‐VAPES (Sapienza University of Rome‐Vascular Assessment of Proatherosclerotic Effects of Smoking) 1 trial.[12](#jah33811-bib-0012){ref-type="ref"} Additional analyses were run solely for descriptive purposes subgrouping by product type. Multilevel mixed‐effects linear analyses are reported as point estimates of effect (95% CIs) and corresponding *P* values. In addition, we performed nonparametric analyses with Wilcoxon signed‐ranks test for satisfaction scores, with reporting based on median (first--third quartile). Although no formal sample‐size computation was performed, the study was originally designed to include 20 nonsmokers and 20 smokers to achieve adequate statistical power, in keeping with a previous study from our group.[12](#jah33811-bib-0012){ref-type="ref"} Because of issues in enrolling nonsmokers and have them use 3 different types of tobacco products, the nonsmoker arm of the study was discontinued at the beginning of the trial. Statistical significance was set at the 2‐tailed 0.05 level, without multiplicity adjustment. Computations were performed with Stata software (version 13; StataCorp LP, College Station, TX).

Results {#jah33811-sec-0017}
=======

The study was conducted between September and December 2017. Notably, as many as 30 subjects had to be excluded after initial screening either because unwilling to refrain from smoking for the required washout period or for the concomitant presence of a clinical condition which qualified them for study exclusion. Table [1](#jah33811-tbl-0001){ref-type="table"} shows baseline characteristics of study subjects: In particular, 70% were women and most usually smoked between 11 and 30 TCs per day. Moreover, 2 women were on oral contraceptives during the experiment.

###### 

Baseline Features

  Subjects                                                                                               20
  ------------------------------------------------------------------------------------------------------ -----------
  Age, y                                                                                                 35±13
  Male sex                                                                                               6 (30%)
  Height, cm                                                                                             171±8
  Weight, kg                                                                                             70±18
  Body mass index, kg/m^2^                                                                               24±5
  Waist‐hip ratio                                                                                        0.92±0.10
  Time since beginning smoking, y                                                                        15±12
  Cigarettes smoked per day                                                                              
  \<10                                                                                                   9 (45%)
  11 to 20                                                                                               9 (45%)
  21 to 30                                                                                               2 (10%)
  Systolic blood pressure, mm Hg                                                                         116±15
  Diastolic blood pressure, mm Hg                                                                        75±10
  Total serum cholesterol, mg/dL                                                                         181±12
  Family history of cardiovascular disease                                                               10 (50%)
  Previous cardiovascular disease                                                                        0
  Concomitant pharmacological therapy (contraceptives, antiepileptics, or thyroid replacement therapy)   5 (25%)

Oxidative Stress Profile {#jah33811-sec-0018}
------------------------

To evaluate oxidative stress profile, we analyzed the levels of sNox2‐dp, a small peptide released after platelet activation, which is a measure of Nox2 activation. As shown in Figure [1](#jah33811-fig-0001){ref-type="fig"} and Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3,](#jah33811-tbl-0003){ref-type="table"} we observed an increase of sNox2‐dp release after smoking each device (19.9±9.9 versus 36.5±6.8 pg/mL, *P*\<0.001 for EVC; 23.1±8.4 versus 44.1±17.1 pg/mL, *P*\<0.001 for TC; 22.8±7.6 versus 29.9±5.0 pg/mL, *P*\<0.001 for HNBC; Table [S1](#jah33811-sup-0001){ref-type="supplementary-material"}). Moreover, we evaluated the production of H~2~O~2~, a nonradical oxygen species which permeates through cell membranes which is chemically stable. The results showed a significant increase of H~2~O~2~ for each smoking device (7.4±3.4 versus 14.8±2.9 μmol/L, *P*\<0.001 for EVC; 7.6±4.5 versus 19.5±13.9 μmol/L, *P*\<0.001 for TC; 6.3±3.5 versus 12.8±3.6 μmol/L, *P*\<0.001 for HNBC; Figure [S2](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}).

![Impact of using electronic cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on blood levels of soluble Nox2‐derived peptide. Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.](JAH3-8-e010455-g001){#jah33811-fig-0001}

###### 

Descriptive Analysis[a](#jah33811-note-0005){ref-type="fn"}

  Feature                                Before Smoking   After Smoking                                        
  -------------------------------------- ---------------- --------------- ----------- ----------- ------------ -----------
  Soluble Nox2‐derived peptide, pg/mL    19.9±9.9         23.1±8.4        22.8±7.6    36.5±6.8    44.1±17.1    29.9±5.0
  Nitric oxide bioavailability, μmol/L   24.9±13.6        25.8±18.9       24.4±16.5   17.0±5.4    12.7±6.6     19.8±6.6
  H~2~O~2~ production, μmol/L            7.4±3.4          7.6±4.5         6.3±3.5     14.8±2.9    19.5±13.9    12.8±3.6
  H~2~O~2~ breakdown activity, %         54.5±18.4        54.1±17.1       55.4±9.9    37.3±7.6    25.3±13.0    47.0±10.2
  8‐iso‐prostaglandin F‐2α‐III, pmol/L   151±18           152±20          158±23      231±31      276±29       207±36
  Vitamin E, μmol/mmol                   4.27±1.30        3.95±1.62       4.11±1.09   2.71±1.07   2.55±0.91    3.81±1.37
  Soluble CD40 ligand, ng/mL             3.20±1.16        3.10±1.22       3.00±1.22   4.25±2.12   5.26±1.97    4.18±1.56
  Soluble P‐selectin, ng/mL              6.45±1.07        6.76±1.28       6.63±1.22   7.97±1.65   11.58±3.56   8.03±1.40
  Flow‐mediated dilation, %              6.14±3.17        6.20±3.26       6.10±3.01   3.72±3.14   2.40±1.89    3.79±2.68
  Systolic blood pressure, mm Hg         121.7±6.5        121.5±8.3       122.8±6.2   130.6±6.5   132.4±6.2    129.7±6.4
  Diastolic blood pressure, mm Hg        72.2±4.4         73.3±4.8        73.3±4.7    78.0±4.8    80.2±5.2     76.9±5.0
  Mean blood pressure, mm Hg             88.7±3.6         89.4±4.7        89.8±4.4    95.5±3.6    97.6±3.4     94.5±4.1
  Cotinine, ng/mL                        31.6±16.6        34.4±19.3       30.4±12.0   64.4±11.1   65.5±10.2    61.0±16.7

EVC indicates electronic vaping cigarette; HNBC, heat‐not‐burn cigarette; TC, traditional tobacco cigarette.

Reported as mean±SD.

###### 

Main Inferential Analysis[a](#jah33811-note-0007){ref-type="fn"}

  Feature                        Before vs After Smoking *P* Value   Interaction *P* Value                               
  ------------------------------ ----------------------------------- ----------------------- --------- --------- ------- ---------
  Soluble Nox2‐derived peptide   \<0.001                             \<0.001                 \<0.001   0.318     0.004   0.001
  Nitric oxide bioavailability   0.006                               0.006                   0.206     0.308     0.470   0.093
  H~2~O~2~ production            \<0.001                             \<0.001                 \<0.001   0.092     0.522   0.042
  H~2~O~2~ breakdown activity    \<0.001                             \<0.001                 0.006     0.038     0.091   \<0.001
  8‐iso‐prostaglandin F‐2α‐III   \<0.001                             \<0.001                 \<0.001   \<0.001   0.004   \<0.001
  Vitamin E                      \<0.001                             0.001                   0.422     0.768     0.018   0.044
  Soluble CD40 ligand            0.047                               \<0.001                 0.007     0.046     0.849   0.071
  Soluble P‐selectin             \<0.001                             \<0.001                 \<0.001   \<0.001   0.821   \<0.001
  Flow‐mediated dilation         \<0.001                             \<0.001                 \<0.001   0.074     0.872   0.048
  Systolic blood pressure        \<0.001                             \<0.001                 \<0.001   0.121     0.122   0.002
  Diastolic blood pressure       \<0.001                             \<0.001                 0.009     0.532     0.106   0.046
  Mean blood pressure            \<0.001                             \<0.001                 \<0.001   0.306     0.053   0.009
  Cotinine                       \<0.001                             \<0.001                 \<0.001   0.782     0.722   0.935

EVC indicates electronic vaping cigarette; HNBC, heat‐not‐burn cigarette; TC, traditional tobacco cigarette.

Reported as *P* values, whereas point estimates of effect (95% CIs) are reported in Table [S1](#jah33811-sup-0001){ref-type="supplementary-material"}.

Finally, we analyzed 8‐iso‐PGF2α, an isoprostane produced by the nonenzymatic peroxidation of arachidonic acid in membrane phospholipids, which is a reliable biomarker of oxidative damage in vivo. We observed a significant increase of 8‐iso‐PGF2α production after smoking (151±18 versus 231±31, *P*\<0.001 for EVC; 152±20 versus 276±29, *P*\<0.001 for TC; 158±23 versus 207±36, *P*\<0.001 for HNBC; Figure [S3](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}). Furthermore, as reported in Table [2](#jah33811-tbl-0002){ref-type="table"}, we observed that levels of oxidative stress biomarkers returned to baseline before each exposure given the adequate washout period.

Antioxidant Status {#jah33811-sec-0019}
------------------

Antioxidant systems, which include enzymatic and nonenzymatic antioxidants, play a role in blocking harmful effects of reactive oxygen species. In this study, we evaluated levels of vitamin E, a powerful endogenus nonenzymatic antioxidant, and HBA, which is a measure of H~2~O~2~ neutralized by cellular enzymes. The results showed a significantly decrease of vitamin E levels after using EVC and TC (4.27±1.30 versus 2.71±1.07 μmol/mmol, *P*\<0.001 for EVC; 3.95±1.62 versus 2.55±0.91 μmol/mmol, *P*\<0.001 for TC; Figure [S4](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}). No changes were observed for vitamin E levels after using HNBC (4.11±1.09 versus 3.81±1.37 μmol/mmol, *P*=0.422; Figure [S3](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}). As regards HBA measurement, we observed a significant reduction in the ability to detoxify H~2~O~2~ after EVC and TC (54.5±18.4% versus 37.3±7.6%, *P*\<0.001 for EVC; 54.1±17.1% versus 25.3±13.0%, *P*\<0.001 for TC; Figure [S5](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}). A similarly significant reduction was observed for HBA after HNBC (55.4±9.9% versus 47.0±10.2%, *P*=0.006; Figure [S3](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}).

Biomarkers of antioxidant status returned to baseline levels before repeat exposure to each smoke device (Table [2](#jah33811-tbl-0002){ref-type="table"}).

Platelet Activation Assessment {#jah33811-sec-0020}
------------------------------

To evaluate the role of different devices on platelet function, we analyzed 2 markers of platelet activation: sCD40L and soluble P‐selectin. Results showed a significant increase in sCD40L levels with each device (3.20±1.16 versus 4.25±2.12 ng/mL, *P*=0.047 for EVC; 3.10±1.22 versus 5.26±1.97 ng/mL, *P*\<0.001 for TC; 3.00±1.22 versus 4.18±1.56 ng/mL, *P*=0.007 for HNBC; Figure [S6](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}) and similar findings for soluble P‐selectin (6.45±1.07 versus 7.97±1.65 ng/mL, *P*\<0.001 for EVC; 6.76±1.28 versus 11.58±3.56 ng/mL, *P*\<0.001 for TC; 6.63±1.22 versus 8.03±1.40 ng/mL, *P*\<0.001 for HNBC; Figure [S7](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}). Biomarkers of platelet activation returned to baseline levels before repeat exposure to each smoke device (Table [2](#jah33811-tbl-0002){ref-type="table"}).

Endothelial Dysfunction {#jah33811-sec-0021}
-----------------------

We evaluated the impact of smoking on endothelial dysfunction analyzing FMD, NO bioavailability, and blood pressure. FMD analysis showed a significantly reduction after using each device (6.14±3.17% versus 3.72±3.14%, *P*\<0.001 for EVC; 6.20±3.26% versus 2.40±1.89%, *P*\<0.001 for TC; 6.10±3.01% versus 3.79±2.68%, *P*\<0.001 for HNBC; Figure [2](#jah33811-fig-0002){ref-type="fig"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}). Similar results were observed for systolic blood pressure (121.7±6.5 versus 130.6±6.5 mm Hg, *P*\<0.001 for EVC; 121.5±8.3 versus 132.4±6.2 mm Hg, *P*\<0.001 for TC; 122.8±6.2 versus 129.7±6.4 mm Hg, *P*\<0.001 for HNBC; Figure [S8](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}), diastolic blood pressure (72.2±4.4 versus 78.0±4.8 mm Hg, *P*\<0.01 for EVC; 73.3±4.8 versus 80.2±5.2 mm Hg, *P*\<0.01 for TC; 73.3±4.7 versus 76.9±5.0 mm Hg, *P*\<0.01 for HNBC; Figure [S9](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}), and mean blood pressure (88.7±3.6 versus 95.5±3.6 mm Hg, *P*\<0.001 for EVC; 89.4±4.7 versus 97.6±3.4 mm Hg, *P*\<0.001 for TC; 89.8±4.4 versus 94.5±4.1 mm Hg, *P*\<0.001 for HNBC; Figure [S10](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}).

![Impact of using electronic cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on flow‐mediated dilation (FMD). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.](JAH3-8-e010455-g002){#jah33811-fig-0002}

Focusing on NO bioavailability, we observed a significant reduction after EVC and TC (24.9±13.6 versus 17.0±5.4 μmol/L, *P*=0.006 for EVC; 25.8±18.9 versus 12.7±6.6 μmol/L, *P*=0.006 for TC; Figure [S11](#jah33811-sup-0001){ref-type="supplementary-material"}; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}). Conversely, NO bioavailability did not change nonsignificantly with HNBCs (24.4±16.5 versus 19.8±6.6 μmol/L, *P*=0.206; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}). Finally, parameters of endothelial dysfunction returned to baseline levels before each repeat exposure (Table [2](#jah33811-tbl-0002){ref-type="table"}).

Compliance Analysis {#jah33811-sec-0022}
-------------------

To evaluate smoking compliance, we analyzed serum levels of cotinine, a metabolite of nicotine and the primary biomarker for the determination of tobacco exposure, before and after smoking. The results showed that all tobacco products increased significantly cotinine levels (*P*\<0.001 for all; Tables [2](#jah33811-tbl-0002){ref-type="table"} and [3](#jah33811-tbl-0003){ref-type="table"}).

Head‐to‐Head Comparisons of HNBC, EVC, and TC {#jah33811-sec-0023}
---------------------------------------------

HNBC and EVC were equally less impactful than TC for HBA, soluble CD40 ligand, and soluble P‐selectin (both *P*\<0.05 versus TC, *P*\>0.05 for HNBC versus EVC). Similar trends were found for FMD (*P*=0.872 for HNBC versus EVC; *P*=0.048 for HNBC versus TC; *P*=0.074 for EVC versus TC), H~2~O~2~ (*P*=0.522 for HNBC versus EVC; *P*=0.042 for HNBC versus TC; *P*=0.092 for EVC versus TC), systolic blood pressure (*P*=0.122 for HNBC versus EVC; *P*=0.002 for HNBC versus TC; *P*=0.121 for EVC versus TC), diastolic blood pressure (*P*=0.106 for HNBC versus EVC; *P*=0.046 for HNBC versus TC; *P*=0.532 for EVC versus TC), and mean blood pressure (*P*=0.053 for HNBC versus EVC; *P*=0.009 for HNBC versus TC; *P*=0.306 for EVC versus TC). Conversely, HNBC were significantly less impactful than EVC and TC on soluble Nox2‐derived peptide (respectively *P*\<0.001 and *P*=0.004) and vitamin E (respectively *P*=0.044 and 0.018). Conversely, we found no nominally significant interaction effects for NO bioavailability or cotinine.

Satisfaction Scores {#jah33811-sec-0024}
-------------------

Exploratory analysis of satisfaction scores (Table [4](#jah33811-tbl-0004){ref-type="table"}) suggested that TC were more enjoyable than both HNBC and EVC (both *P*\<0.05; Figure [S12](#jah33811-sup-0001){ref-type="supplementary-material"}). In addition, EVC proved less satisfying than both TC (*P*=0.017) and HNBC (*P*=0.038), without significant differences between these 2 (*P*=0.239; Figure [S13](#jah33811-sup-0001){ref-type="supplementary-material"}). Similarly, EVC were rated as less likely to decrease desire for another cigarette than TC (*P*=0.019) and HNBC (*P*=0.031), without significant differences between these 2 (*P*=0.581; Figure [S14](#jah33811-sup-0001){ref-type="supplementary-material"}).

###### 

Satisfaction Scores[a](#jah33811-note-0010){ref-type="fn"}

  Feature                                                              Median (First--Third Quartile)   *P* Value                                    
  -------------------------------------------------------------------- -------------------------------- -------------- ------------- ------- ------- -------
  Was the cigarette satisfying?                                        0 (0--50)                        63 (38--75)    50 (25--75)   0.017   0.038   0.239
  Was the cigarette enjoyable?                                         25 (0--50)                       75 (50--88)    50 (25--75)   0.007   0.073   0.038
  Did you experience a bad taste?                                      0 (0--50)                        0 (0--50)      25 (0--75)    0.895   0.353   0.435
  Did you suffer from unexpected cough?                                0 (0--0)                         0 (0--0)       0 (0--0)      0.970   0.361   0.305
  Did smoking make you feel sick?                                      0 (0--0)                         0 (0--0)       0 (0--0)      1       0.564   0.317
  Did smoking give you energy?                                         0 (0--25)                        0 (0--25)      0 (0--25)     0.882   0.910   0.471
  Soon after smoking did your desire for another cigarette decrease?   25 (0--50)                       75 (25--100)   75 (25--75)   0.019   0.031   0.581

EVC indicates electronic vaping cigarette; HNBC, heat‐not‐burn cigarette; TC, traditional tobacco cigarette.

Scored on a subjective scale from 0 (no effect) to 100 (maximum effect).

Discussion {#jah33811-sec-0025}
==========

In the present cross‐over randomized trial comparing the acute effects of HNBC, EVC, and TC, we found that use of any of these products was associated with acute detrimental effects on oxidative stress, antioxidant reserve, platelet function, FMD, and blood pressure.

The validity of the chosen end points is well established. Indeed, systemic oxidative stress plays a fundamental role in vascular damage and in atherogenesis.[23](#jah33811-bib-0023){ref-type="ref"} Reactive oxygen species are mostly generated by Nox2, an isoform from NADPH oxidase, that acts as an important regulator of platelet‐activation--associated thrombosis.[24](#jah33811-bib-0024){ref-type="ref"} Indeed, Nox2 has been shown to be associated with several cardiovascular risk factors, such as hypercholesterolemia[25](#jah33811-bib-0025){ref-type="ref"} and metabolic diseases,[26](#jah33811-bib-0026){ref-type="ref"}, [27](#jah33811-bib-0027){ref-type="ref"} and in patients with peripheral artery disease.[28](#jah33811-bib-0028){ref-type="ref"} Moreover, 8‐iso‐PGF2α and H~2~O~2~ production and endhotelial dysfunction are associated with cardiovascular events.[28](#jah33811-bib-0028){ref-type="ref"}, [29](#jah33811-bib-0029){ref-type="ref"}, [30](#jah33811-bib-0030){ref-type="ref"}, [31](#jah33811-bib-0031){ref-type="ref"} Regarding physiological antioxidant capacity, the downregulation of the antioxidant system, such as vitamin E or enzymes devolved to H~2~O~2~ detossification, is associated with an increased cardiovascular risk.[32](#jah33811-bib-0032){ref-type="ref"}, [33](#jah33811-bib-0033){ref-type="ref"}

Focusing in detail on our results, a hierarchy of effects was apparent for some measures, with HNBC and EVC less impactful than TC on some dimensions of oxidative stress, antioxidant reserve, platelet function, and blood pressure. In addition, HNBC had less acute effects on soluble Nox2‐derived peptide, 8‐iso‐PGF2α‐III, and vitamin E, and appeared more satisfying and capable of decreasing desire for continuing smoking than EVC.

The adverse impact of TC on health is well established, and smoking remains a leading preventable cause of morbidity and mortality worldwide.[34](#jah33811-bib-0034){ref-type="ref"} Despite the lack of combustion and while less detrimental than TC, EVC cannot be considered harmless.[9](#jah33811-bib-0009){ref-type="ref"}, [12](#jah33811-bib-0012){ref-type="ref"}, [35](#jah33811-bib-0035){ref-type="ref"}, [36](#jah33811-bib-0036){ref-type="ref"}, [37](#jah33811-bib-0037){ref-type="ref"}, [38](#jah33811-bib-0038){ref-type="ref"} The manufacturer of HNBC claims that they largely avoid pyrolysis and thus the generation of several harmful molecules, at least in relative terms, although this aspect may warrant additional study by independent investigation.[10](#jah33811-bib-0010){ref-type="ref"} It is also very likely that the acute detrimental effects of HNBC are mediated, at least in part, by nicotine.[39](#jah33811-bib-0039){ref-type="ref"}, [40](#jah33811-bib-0040){ref-type="ref"}

Our findings expand and refine knowledge on the acute comparative effects of HNBC, EVC, and TC and builds upon our recent work comparing EVC and TC for oxidative stress and FMD.[12](#jah33811-bib-0012){ref-type="ref"} The fact that oxidative stress, platelet activation, and blood pressure are less impacted by HNBC and EVC than by TC suggests that they might be less detrimental, whereas some similarities between HNBC and TC, in terms of subjective satisfaction, might make HNBC more suitable than EVC as a risk‐reduction product. Thus, these products cannot be considered equivalent in terms of risk, yet many opinion leaders, advocacy groups, and agencies call for complete abstinence from all products.[41](#jah33811-bib-0041){ref-type="ref"} Others have suggested that a more‐pragmatic risk‐reduction strategy could be more fruitful, at least in the short term.[42](#jah33811-bib-0042){ref-type="ref"} Our study provides information to guide future research on this topic, especially in light of the similar capacity of these products to deliver nicotine, as demonstrated by the nonsignificant interaction *P* values for cotinine.[43](#jah33811-bib-0043){ref-type="ref"}

Our work has, however, several limitations. The first is generalizability: we recruited from a homogeneous nonsmoking white population without overt clinical conditions, thus our findings cannot be directly applied to subjects with different features.[44](#jah33811-bib-0044){ref-type="ref"} We eventually avoided the enrollment of nonsmokers in the study given difficulties in having them smoke 3 types of tobacco products, and also in order to avoid any possible incentive versus EVC or HNBC from the study findings. Indeed, the actual aim of the SUR‐VAPES 2 trial is to provide preliminary data for subsequent longitudinal trials on the use of HNBC and EVC for smoking cessation in smokers with established cardiovascular disease. Conversely, we did not want to provide background for use of EVC or HNBC as a lower‐risk surrogate of TC in nonsmokers. Indeed, exposure to EVC advertisements has been shown to cause increases in smoking impulses among adults who were former smokers or did not smoke at all, reduce teenagers' perceived risks of TC, and be associated with increased odds of EVC and TC use in both cross‐sectional and longitudinal studies.[45](#jah33811-bib-0045){ref-type="ref"}, [46](#jah33811-bib-0046){ref-type="ref"}, [47](#jah33811-bib-0047){ref-type="ref"} Second, the small sample size and exposure period limited to 1 product per session prevent us from providing very precise effect estimates or understanding how strongly the observed trends in oxidative markers are correlated with smoking as opposed to statistical noise. Third, our focus on acute effects of a single smoking session of HNBC, EVC, and TC after an adequate washout cannot inform the chronic comparative impact of these products, and it remains unclear whether these chronic tobacco users may lead to more persistent vascular changes and biochemical profiles that do not represent the direct influence of each exposure. Accordingly, the study lacks longitudinal exposure and follow‐up, decreasing our ability to understand whether the observed advantages of HNBC or EVC over TC from an oxidative standpoint are maintained with repetitive use of these smoking devices, or whether, for example, they lose significance in the long run. Fourth, we did not focus on other important health dimensions, in particular those of pulmonary function and carcinogenesis, which require further investigation. Fifth, given the levels of cotinine at baseline assessments, compliance to washout recommendations was suboptimal. Nevertheless, this did not appear to affect between‐device comparisons. Sixth, we did not adjust for multiplicity, but the mixed‐effect design can be considered relatively robust for multiple inferential estimates. Nonetheless, the risk of type 1 error persists and should be borne in mind by readers. In addition, the mechanistic impact of HNBC and EVC on oxidative stress, FMD, and platelet function was not addressed in detail in our work, which was designed with a pragmatic scope.[45](#jah33811-bib-0045){ref-type="ref"}, [46](#jah33811-bib-0046){ref-type="ref"} Details on satisfaction scores, while interesting given their important implications on the use of these approaches as a risk‐reduction strategy, are limited by their exploratory scope and require additional analyses.[47](#jah33811-bib-0047){ref-type="ref"}, [48](#jah33811-bib-0048){ref-type="ref"}, [49](#jah33811-bib-0049){ref-type="ref"} Finally, the absence of a control group not receiving any tobacco product or an experimental group using a pure nicotine inhaler did not allow us to provide external baseline and repeated measures, nor focus specifically on the effect of selective nicotine administration on oxidative stress, FMD, and platelet activation.

In conclusion, while our findings should be regarded as preliminary and needing confirmation in other similar experiments, we found that use by a group of healthy adult smokers of HNBC, EVC, and TC, based on equivalent nicotine consumption, was associated with acute multidimensional adverse effects on a range of biological and physiological markers. The finding that HNBC is less impactful than both EVC and TC for some end points, while intriguing, requires further corroboration in larger studies with cohort design, long‐term follow‐up, and clinically relevant end points.
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**Data S1.** Additional details on statistical analysis.

**Table S1.** Additional Inferential Analysis

**Figure S1.** Consolidated Standards of Reporting Trials (CONSORT) subject flow diagram (left panel) and measurement protocol (right panel). BP indicates blood pressure; EVC, electronic vaping cigarette; FMD, flow‐mediated dilation; HNBC, heat‐not‐burn cigarette; TC, traditional tobacco cigarette.

**Figure S2.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on H~2~O~2~ production. Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S3.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on 8‐iso‐prostaglandin F‐2α‐III (8‐iso‐PGF2a). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S4.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on vitamin E. Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S5.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on H~2~O~2~ breakdown activity (HBA). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S6.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on soluble CD40 ligand. Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S7.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on soluble P‐selectin. Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S8.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on systolic blood pressure (SBP). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S9.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on diastolic blood pressure (DBP). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S10.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on mean blood pressure (MBP). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S11.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on nitric oxide (NO) bioavailability. Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S12.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on smoking satisfaction, appraised with the explicit question "Was the cigarette enjoyable?", and answers scored using a subjective scale from 0 (no effect) to 100 (maximum effect). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S13.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on smoking satisfaction, appraised with the explicit question "Was the cigarette satisfying?", and answers scored using a subjective scale from 0 (no effect) to 100 (maximum effect). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.

**Figure S14.** Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat‐not‐burn cigarette (HNBC) on smoking satisfaction, appraised with the explicit question "Soon after smoking did your desire for another cigarette decrease?", and answers scored using a subjective scale from 0 (no effect) to 100 (maximum effect). Box plots represent median, first quartile, third quartile, fifth percentile, 95th percentile, and outliers.
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